Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBP-301 in unresectable metastatic melanoma
NCT03190824Phase 2Unknown
- Sponsor
- Syneos Health
- Start
- Dec 2016
- Primary completion
- Jun 2021
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of suratadenoturev in melanoma, sponsored by Syneos Health. Status: unknown.
02
Drugs
suratadenoturev
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03190824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03190824.